arrow left
arrow right
  • xxxxxx xxxxxxxx, xxxxx xxxxxxxx v. Ronald J Tadeo, Richard Pitch, Scott Berlin, Shore Psychiatric Center, Family Psychology Of Long Island, Berlin Obgyn Associates, Janssen Pharmaceuticals, Inc. K/N/A Ortho-Mcneil-Janssen Pharmaceuticals, Inc., Zydus Pharmaceuticals Usa, Inc. Tort document preview
  • xxxxxx xxxxxxxx, xxxxx xxxxxxxx v. Ronald J Tadeo, Richard Pitch, Scott Berlin, Shore Psychiatric Center, Family Psychology Of Long Island, Berlin Obgyn Associates, Janssen Pharmaceuticals, Inc. K/N/A Ortho-Mcneil-Janssen Pharmaceuticals, Inc., Zydus Pharmaceuticals Usa, Inc. Tort document preview
  • xxxxxx xxxxxxxx, xxxxx xxxxxxxx v. Ronald J Tadeo, Richard Pitch, Scott Berlin, Shore Psychiatric Center, Family Psychology Of Long Island, Berlin Obgyn Associates, Janssen Pharmaceuticals, Inc. K/N/A Ortho-Mcneil-Janssen Pharmaceuticals, Inc., Zydus Pharmaceuticals Usa, Inc. Tort document preview
  • xxxxxx xxxxxxxx, xxxxx xxxxxxxx v. Ronald J Tadeo, Richard Pitch, Scott Berlin, Shore Psychiatric Center, Family Psychology Of Long Island, Berlin Obgyn Associates, Janssen Pharmaceuticals, Inc. K/N/A Ortho-Mcneil-Janssen Pharmaceuticals, Inc., Zydus Pharmaceuticals Usa, Inc. Tort document preview
  • xxxxxx xxxxxxxx, xxxxx xxxxxxxx v. Ronald J Tadeo, Richard Pitch, Scott Berlin, Shore Psychiatric Center, Family Psychology Of Long Island, Berlin Obgyn Associates, Janssen Pharmaceuticals, Inc. K/N/A Ortho-Mcneil-Janssen Pharmaceuticals, Inc., Zydus Pharmaceuticals Usa, Inc. Tort document preview
  • xxxxxx xxxxxxxx, xxxxx xxxxxxxx v. Ronald J Tadeo, Richard Pitch, Scott Berlin, Shore Psychiatric Center, Family Psychology Of Long Island, Berlin Obgyn Associates, Janssen Pharmaceuticals, Inc. K/N/A Ortho-Mcneil-Janssen Pharmaceuticals, Inc., Zydus Pharmaceuticals Usa, Inc. Tort document preview
  • xxxxxx xxxxxxxx, xxxxx xxxxxxxx v. Ronald J Tadeo, Richard Pitch, Scott Berlin, Shore Psychiatric Center, Family Psychology Of Long Island, Berlin Obgyn Associates, Janssen Pharmaceuticals, Inc. K/N/A Ortho-Mcneil-Janssen Pharmaceuticals, Inc., Zydus Pharmaceuticals Usa, Inc. Tort document preview
  • xxxxxx xxxxxxxx, xxxxx xxxxxxxx v. Ronald J Tadeo, Richard Pitch, Scott Berlin, Shore Psychiatric Center, Family Psychology Of Long Island, Berlin Obgyn Associates, Janssen Pharmaceuticals, Inc. K/N/A Ortho-Mcneil-Janssen Pharmaceuticals, Inc., Zydus Pharmaceuticals Usa, Inc. Tort document preview
						
                                

Preview

MARTIN CLEARWATER & BELL LLP COUNSELORS AT LAW 90 MERRICK AVENUE, SUITE 401, EAST MEADOW, NY 11554 TELEPHONE (516) 222-8500 FACSIMILE (516) 222-8513 www.mcblaw.com NEW YORK, NY EAST MEADOW, NY WHITE PLAINS, NY ANINA H. MONTE ROSELAND, NJ PARTNER ROCHESTER, NY DIRECT DIAL: (516) 712-3141 STAMFORD, CT E-MAIL: anina.monte@mcblaw.com June 13, 2023 Via NYSCEF Hon. C. Stephen Hackeling Justice of the Supreme Court, IAS Part 12 Suffolk County Supreme Court One Court Street Riverhead, New York 11901 Re: xxxxxxxx, xxxxxx V. RONALD J. TADEO, M.D., ET AL. Index No. 026910/2012 MCB File No. 00033-087918 Dear Honorable Justice Hackeling: As Your Honor is aware our office represents the interests of the defendants, Ronald J. Taddeo, M.D. s/h/a Ronald J. Tadeo, M.D. and Shore Psychiatric Center, in the above-referenced matter. I write to advise the Court of an objection I will be placing on the record prior to the closing arguments in this case. It is my intention to raise this objection based upon what I believe Mr. xxxxxxx will assert is proper and just compensation for the damages in this case. This letter and objection is based upon the representations made by Mr. xxxxxxx during our in camera discussions on this case, in addition to comments made during voir dire. I have a good faith basis to believe that in his closing argument Mr. xxxxxxx will refer to improper anchoring and a suggestion of a jury award that is far greater than the sustainable amount for the alleged damage of cleft lip and cleft palate. As the Court is aware, noneconomic damages are highly subjective and inherently unpredictable. There is no standard measurement of pain and suffering or “even a conception of those damages or what they represent.” Dan B. Dobbs, Law of Remedies 8.1(4), at 383 (2d ed. 1993). Consequently, juries can be significantly influenced by a figure given to them by plaintiffs’ counsel. In the late 1950s and 1960s, plaintiffs’ lawyers began employing this controversial, though now ubiquitous, practice, routinely asking jurors to award an extraordinary amount for pain and suffering. See, xxxxxx H. King, Jr., Counting Angles and Weighing Anchors: Per Diem Arguments for Noneconomic Personal Injury Tort Damages, 71 Tenn. L. Rev. 1, 13 (2003). An “anchor” provided by plaintiffs’ counsel establishes an arbitrary, but psychologically powerful AHM/le 4894179_1 June 13, 2023 Page 2 baseline for jurors struggling with assigning a monetary value to pain and suffering. See, Id. at 37- 40. Jurors may accept the suggested amount or “compromise” by negotiating it upward or downward. While any category of damages can be influenced by anchoring, the practice has the greatest impact with respect to noneconomic damages, since pain and suffering is the least susceptible to quantification. See, Don Rushing, et al., Anchors Away: Attacking Dollar Suggestions for Non-Economic Damages in Closings, Def. Counsel J. 378, 381 (July 2013). New York has experienced an upward trend in pain and suffering awards as a result of anchoring tactics. See, Timothy R. Capowski & John F. Watkins, CPLR §5501(c) Review in the Age of Summation ‘Anchoring’ Abuse, N.Y.L.J., June 26, 2019. However, urging juries to return extraordinary sums for pain and suffering is improper because these damages are intended to “restore the injured party, to the extent possible, to the position that would have been occupied had the wrong not occurred.” McDougald v. Garber, 73 N.Y.2d 246, 253-54 (1989) (citation omitted). As the Court of Appeals has recognized, awards for pain and suffering rest on “the legal fiction that money damages can compensate for a victim’s injury.” Id. at 254 (quoting, Howard v. Lecher, 42 N.Y.2d 109, 111 (1977)). Courts know that money cannot replace a lost limb or remove a disability, but award damages “in [an] effort to right the wrong.” Id. The purpose of the award of damages is to “compensate the victim, not to punish the wrongdoer.” Id. The Court of Appeals’ “willingness to indulge this fiction comes to an end, however, when [an award for noneconomic loss] ceases to serve the compensatory goals of tort recovery.” Id. Valuing pain and suffering by the amount that a juror would accept to trade places with the plaintiff is one measure long recognized as excessive. See, e.g., Liosi v. Vaccaro, 35 A.D.2d 790 (1st Dep’t 1970). Moreover, any award that is intended to punish a tortfeasor for his or her conduct or deter similar actions in the future ceases to be compensatory. See, Sharapata v. Islip, 56 N.Y.2d 332, 335 (1982). Punitive damages are warranted only for “wrongful conduct that goes beyond mere negligence.” Chauca v. Abraham, 30 N.Y.3d 325, 331-32 (2017). Such damages are rightly subject to substantive and procedural constitutional safeguards. See, e.g., BMW of N. Am., Inc. v. Gore, 517 U.S. 559, 575-83 (1996) (providing constitutional guideposts for evaluating whether a punitive damage award is excessive); See also, Victor E. Schwartz & Leah Lorber, Twisting the Purpose of Pain and Suffering Awards: Turning Compensation Into “Punishment,” 54 S.C. L. Rev. 47, 49 (2002) (predicting that without proper oversight by courts, plaintiffs’ counsel will use pain and suffering awards to punish a defendant without the safeguards applicable to punitive damage awards). CPLR §4016 permits an attorney to suggest that the jury award a particular amount of compensation. However, requesting an amount that cannot possibly be sustained under CPLR §5501(c) as “reasonable compensation” is improper and unduly prejudicial. In the face of the 1980s financial crisis that led to spiraling insurance premiums, Mario Cuomo’s “Governor’s Advisory Commission,” chaired by former Court of Appeals Judge Hugh Jones, drafted a report of recommendations and observations that ultimately led to the enactment of CPLR §5501(c). The Jones Commission recognized that jurors are inclined to award ever-higher amounts to compensate for a person’s pain and suffering: [a]ll of us are moved by the pain and anxiety that most people who suffer more than minor injuries go through. Our natural tendency is to want to help. Inasmuch as there is no objective way to value these harms, our inclination is to err on the high side. Over 4894179_1 June 13, 2023 Page 3 time, this tendency gathers its own momentum, a momentum which has no natural curbing force. Particularly in an era where the existence of insurance is commonly assumed, so that the defendant is not expected to bear most of the loss, the urge to provide the most assistance possible becomes nearly irresistible. Donlon v. City of New York, 284 A.D.2d 13, 15 (1st Dep’t 2001) (quoting, Hugh R. Jones, Insuring Our Future—Report of the Governor’s Advisory Commission on Liability Insurance, Apr. 7, 1986, at 85). As the Court of Appeals recently noted, the Jones Commission found that the expansion of tort liability in New York State led to insurance prices that businesses could not afford, and that courts had been blind to “the health of the risk-spreading mechanism that American society . . . developed to assure that compensation is in fact available for those who are entitled to receive it.” Artibee v. Home Place Corp., 28 N.Y.3d 739, 751 (2017) (quoting Insuring Our Future at128). The Commission observed that ‘the ends of justice are subverted when insurance is unavailable at an affordable price.” Id. (quoting Insuring Our Future at 128). While the $250,000 “hard cap” on noneconomic damages proposed by the Jones Commission was not adopted, the legislative compromise that followed was the rejection of the deferential common law “shocks the conscience” standard and the enactment of CPLR §5501(c). The replacement—that “deviates materially” formulation—was specifically enacted to stop the upward spiral of awards by “tightening the range of tolerable awards.” Donlon, 284 A.D.2d at 16 (quoting, Gasperini v. Center for Humanities, 518 U.S. 415, 425 (1996)). CPLR §5501(c) sought to decrease uncertainty as to the value of injuries and increase fairness to similarly situated plaintiffs and defendants, and to facilitate settlements and reduce the strain on judicial resources. See, Gasperini, 518 U.S. at 423-25; Consorti v. Armstrong World Industries, Inc., 72 F.3d 1003, 1009-10, 1013 and n.10, 1014-16 (2d Cir. 1995), vacated on other grounds, 518 U.S. 1031 (1996). Those objectives are not served when plaintiffs’ counsel, with increasing frequency, urge juries to award amounts for pain and suffering that are well beyond the permissible range of “reasonable compensation” established by the appellate courts of New York pursuant to CPLR §5501(c). As no objective formula assigning a monetary value to pain and suffering exists, achieving an evenhanded, fair, and predictable system requires courts to use their authority under CPLR §5501(c) to “exercise responsibility to keep jury awards within limit.” Consorti, 72 F.3d at 1009. Alternatively, “[w]hen courts fail to exercise the responsibility to curb excessive verdicts, the effects are uncertainty and an upward spiral. One excessive verdict, permitted to stand, becomes precedent for another still larger one.” Id. at 1010. Accordingly, it is respectfully requested that the Court apply the standard of CPLR §5501(c) to constrain abusive anchoring tactics and to address the subjective, unpredictable nature of pain and suffering awards. In New York, CPLR §5501(c) provides courts with the primary means for keeping pain and suffering awards in a predictable and fair range. The Court should apply the approach set forth in that law to preclude the plaintiff’s attorney in this case from suggesting that the jury award an artificially high amount for pain and suffering, which is well outside the range established by New York Courts in medical malpractice cases. Mr. xxxxxxx has indicated he will base his jury demand upon the Topamax litigation and the awards issued therein. That litigation was not in New York and not a medical malpractice, but rather a Pharmaceutical 4894179_1 June 13, 2023 Page 4 case, which, while it involved the same drug at issue, demonstrated a far different set of circumstances, standard of law, and factual scenario. When plaintiffs’ attorneys suggest amounts never before sustained as “reasonable” in New York courts, they mislead jurors. Worse, defense counsel has no way of rebutting this, and cannot even present the jury with the sustainable range based on case law, which is (a) not evidence before the jury; and (b) a legal, not factual, argument, and thus not properly presented to a jury in any event. The result is a paradox: plaintiffs’ counsel is free to suggest any number to the jury, as long as that number is not specifically tied to any precedent. This undermines the goals of CPLR §5501(c), which sought to arrest the upward spiral of pain and suffering awards by tethering them to precedent. To be clear, on behalf of the defense I am not asking the court to issue a blanket ruling preventing counsel from making a suggestion to the jury for pain and suffering, as this is expressly authorized by CPLR §4016(b). Rather, I am suggesting that the Court constrain anchoring tactics via the key language of CPLR §4016(b)—which only permits suggesting a level that constitutes “appropriate compensation” to a jury, not a wildly inflated amount that cannot be sustained on appeal. In addition, “appropriate compensation” for pain and suffering must be consistent with CPLR §5501(c), which indicates that an award will not be sustained if it “deviates materially from what would be reasonable compensation” based on a comparative approach to analogous cases. I thank you for your consideration herein. Very truly yours, MARTIN CLEARWATER & BELL LLP Anina H. Monte CC: All Parties Via NYSCEF 4894179_1